Vor Biopharma Inc.

Exicure, Inc.

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

Northwestern University

Exicure Operating Company

Harvard College

Aleksandar Filip Radovic-Moreno

Joseph Beene Bolen

John Lydeard

Sergei M Gryaznov

Christopher C Mader

Robert Samuel Langer

Omid C Farokhzad

Subbarao Nallagatla

Chad A Mirkin

SonBinh T Nguyen

Richard Kang

Natalia Chernyak

Resham Singh Banga

Liangfang Zhang

Aaron Love

Warefta Hasan

Sergei Gryaznov

Ulrich Von Andrian

Gershon Golomb

Pamela A Basto

Frank Alexis

Weiwei Gao

Frank X Gu

Michael N Starnbach

Robert Langer

Archana Swami

Georg Stary

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Genetically engineered hematopoietic stem cells and uses thereof

Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.

Compositions and methods for inhibition of lineage specific proteins

Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.

Liposomal particles, methods of making same and uses thereof

Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease

Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use

Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.

Growing community of inventors

Evanston, IL, United States of America

Aleksandar Filip Radovic-Moreno